Logo
x

Search

Subscribe Now

Reduce

BridgeBio and Origin's Nulibry (fosdenopterin) Receives the US FDA's Approval as the First Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A

BridgeBio and Origin's Nulibry (fosdenopterin) Receives the US FDA's Approval as the First Therapy to Reduce the Risk of Mortality...

  • March 1, 2021
NightWare Receives the US FDA's Approval for the First Medical Device to Stop NightMAres Related to PTSD

NightWare Receives the US FDA's Approval for the First Medical Device to Stop NightMAres Related to PTSD

  • November 11, 2020
Merck and Bayer Receive the US FDA's Priority Review for Vericiguat to Reduce the Risk of CV Death in Patients with Symptomatic Chronic Heart Failure with HFrEF

Merck and Bayer Receive the US FDA's Priority Review for Vericiguat to Reduce the Risk of CV Death in Patients with Symptomatic Ch...

  • July 16, 2020
Baysient to Release iDose Software Technology Platform 1.0 to Reduce the Biosimilar Cost in Market

Baysient to Release iDose Software Technology Platform 1.0 to Reduce the Biosimilar Cost in Market

  • February 28, 2020
Eli Lilly's Trulicity (dulaglutide) Receives the US FDA's Approval to Reduce MACE in T2D Adults

Eli Lilly's Trulicity (dulaglutide) Receives the US FDA's Approval to Reduce MACE in T2D Adults

  • February 24, 2020
Astellas Reports Results of Mirabegron in P-IV PLUS Study to Reduce Overactive Bladder Symptoms in Men

Astellas Reports Results of Mirabegron in P-IV PLUS Study to Reduce Overactive Bladder Symptoms in Men

  • May 6, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.